Phase III Clinical Trial for OGX_011 – A Treatment for Failed Chemotherapy

At the last ASCO Annual Meeting Saad et al. presented a report about a Phase II trial of custirsen (OGX-011) + docetaxel + prednisone vs. custirsen + mitoxantrone + prednisone in metastatic hormone-refractory prostate cancer. The subjects in the study had experienced relapses of cancer progression within 6 months of treatment with first-line docetaxel therapy. [...]